Mechanical heart pump devices are used to support blood flow and cardiac function in patients with weak hearts. The surgically implanted gadget helps people with weak or irregular hearts perform more effectively for short or long periods of time. The market for heart pump devices is expanding as a result of a number of factors, including the increased incidence of cardiovascular illnesses, the ageing population, new products introduced by prominent market participants, and rising patient demand as a result of heart pump technology developments.
The market for heart pump devices is fueled by a number of causes, including the rising incidence of heart failure. The American Heart Association estimates that 6.2 million adult Americans already have heart failure, and that number will rise to 8 million by 2030. Since heart pump devices offer a life-saving option for patients with end-stage heart failure who are ineligible for heart transplants, this expanding patient population is fueling demand for heart pump devices.
The market is also being stimulated by the rising popularity of minimally invasive procedures. For the treatment of heart failure, minimally invasive procedures are becoming more and more common because they have a number of benefits over open heart surgery, including smaller incisions, less blood loss, and quicker recovery times. The demand for heart pump devices is being driven by the frequent usage of these devices in minimally invasive procedures.
The market for heart pump devices has room for expansion, but it also faces a number of obstacles. The high price of heart pump devices is one difficulty. The expense of these devices for patients and healthcare providers is increased by their pricey manufacturing and the specific training needed to implant and maintain them.
The possibility of difficulties with heart pump devices presents another difficulty. Heart pump devices carry some dangers even though they have been proved to improve patient outcomes and quality of life. Risks might include bleeding, infection, and device malfunction, which can lead to hospital readmissions and increased healthcare expenses.
The market for heart pump devices presents several chances for development and innovation. One chance is the creation of more compact and portable electronics. Presently, implanting heart pump devices requires a significant amount of bodily space due to their size. The spread of this life-saving technology to more patients would be made possible by the development of smaller, more portable devices.
The spread of heart pump devices to new patient populations represents an additional opportunity. Presently, individuals with end-stage heart failure who are ineligible for heart transplants represent the majority of patients who use heart pump devices. Yet, other patient populations, such as those experiencing high-risk cardiac procedures or those with acute heart failure, might also gain advantage from these devices.
The heart pump devices market is divided into five geographic regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Due to rising spending on healthcare research and development, North America is projected to dominate the market for heart pump devices. The dominance is a result of the growing prevalence of geriatric and cardiovascular disorders. For instance, the Public Health Agency of Canada estimates that in Canada, 2.4 million persons aged 20 and older have heart disease. For the entire forecast period, Europe is expected to have the second-largest market share. The creation of new products and joint venture initiatives by significant industry participants are projected to accelerate the growth of the heart pump devices market in this area. Also, the growing elderly population is a factor in this region's market expansion.
Some of the major companies propel to the Heart Pump Devices Market are
The global Heart Pump Devices Market is segmented based on product, device type, therapy, end-user
By Product:
·Ventricular Assist Devices
·Left Ventricular Assist Devices
·Right Ventricular Assist Devices
·Bi-Ventricular Assist Devices
·Percutaneous Ventricular Assist Devices
·Transcutaneous Ventricular Assist Devices
·Intra-Aortic Balloon Pumps
·Total Artificial Heart
By Device Type:
·Implantable Heart Pump Devices
·Extracorporeal Heart Pump Devices
By Therapy:
·Bridge-To-Candidacy (BTC)
·Bridge-To-Transplant (BTT)
·Destination Therapy (DT)
·Others
By End-User:
·Hospitals & Clinics
·Ambulatory Surgical Centers
·Research Institutes
·Others
·Abbott introduced a novel minimally invasive device for the treatment of heart valve problems in India in December 2022. The organization's cardiac trans-catheter portfolio, which provides less invasive solutions for treating heart problems, has recently expanded with the introduction of the Navitor TAVI device.
·Abbott's Completely Implantable Left Ventricular Assist System was given FDA (Food and Drug Administration) breakthrough device designation in March 2020. (FILVAS).
·The "RESONATE" cardiac resynchronization therapy defibrillator (CRT-D) system from Boston Scientific was introduced in Europe in February 2017. A recently released product using SmartCRT technology has the CE mark and is currently offered to patients with heart failure in Europe.
Heart Pump Devices Market